You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 1 to 25 of about 5545
Next 25
03/31/2023
Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial
03/28/2023
Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme
Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5
03/24/2023
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
03/17/2023
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma
03/15/2023
Servier`s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
Drug offers renewed hope to brain cancer patients
Hoops For Hannah Brackets Deadline
03/13/2023
Head to the Hill 2023
03/12/2023
Newly-diagnosed high grade glioma surgery with carmustine wafers implantation. A long-term nationwide retrospective study
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
03/08/2023
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Weil Cornell Medicine webinars on Advances in Brain Tumor Research and Treatments
03/07/2023
Learnings from Pilot Study: Creating Treatment Templates to Serve More Glioblastoma Patients
03/06/2023
Foundation stirs controversy by charging cancer patients $83,000 for unproven but promising experimental drug
Musella Foundation Copay Program now open to new and renewal patients!
02/10/2023
A Critical Analysis of Neuro-Oncology Clinical Trials
Immunotoxin-aCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models
02/08/2023
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma
Musella Foundation Copay Program now closed to new and renewal patients
02/03/2023
OKN-007 Expanded Access for Pediatric Patients with Diffuse Midline Glioma(including DIPG)
01/15/2023
Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial
Drug Against Most Common Pediatric Brain Cancer Achieves Trial Success
01/14/2023
Feinstein Institutes, Northwell Use Ultrasound to Treat Brain Tumors in Novel Clinical Trial
New drug combination may effectively treat often fatal childhood brain tumor